(Circulation. 2005;111:2086-2090.)
© 2005 American Heart Association, Inc.
Hypertension |
From the Centre for Clinical Pharmacology (M.N., A.M., R.S., S. Haworth, P.V.), British Heart Foundation Laboratories, The Rayne Institute, University College London, and the Division of Neuropathology (T.S.J.), Neurometabolic Unit and Division of Neurochemistry (A.A.J.L., S. Heales), Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Correspondence to Manasi Nandi, Centre for Clinical Pharmacology, British Heart Foundation Laboratories, The Rayne Institute, University College London, 5 University St, London WC1E 6JJ, United Kingdom. E-mail m.nandi{at}ucl.ac.uk
Received June 15, 2004; revision received January 14, 2005; accepted January 20, 2005.
Background GTP-cyclohydrolase 1 (GTP-CH1) catalyzes the first step for the de novo production of tetrahydrobiopterin (BH4), a cofactor for nitric oxide synthase (NOS). The hyperphenylalaninemic mutant mouse (hph-1) displays a 90% reduction in GTP-CH1 activity. Reduced BH4 decreases NOS activity and may lead to endothelial dysfunction, and there is increasing evidence that a dysfunction of the NOS pathway may be implicated in pulmonary hypertension. The aim of the study was to investigate whether reduced BH4 in the hph-1 mouse results in a pulmonary hypertensive phenotype.
Methods and Results Morphological characterization of the heart, lung, and kidney and measurements of systemic and right ventricular blood pressures were performed in both hph-1 and wild-type mice. BH4 and NOx levels were also measured. Hph-1 mice had significantly lower NOx and BH4 levels, consistent with previous findings. Both morphological and in vivo data were indicative of a pulmonary but not systemic hypertensive phenotype. We observed increased right ventricleleft ventricle plus septum ratios attributable only to an increase in right ventricular mass, increased smooth muscle medial area in pulmonary resistance vessels, and significantly higher right ventricular pressures in vivo. There were no significant differences between left ventricular masses and systemic pressures, and there was no observed evidence of systemic hypertension in kidney sections between wild-type and hph-1.
Conclusions This study demonstrates that mice deficient in GTP-CH1/BH4 display a pulmonary hypertensive but not systemic hypertensive phenotype.
Key Words: hypertension, pulmonary nitric oxide synthase remodelling
Related Article:
Circulation 2005 111: 2022-2024.
This article has been cited by other articles:
![]() |
K. N. Farrow, S. Lakshminrusimha, W. J. Reda, S. Wedgwood, L. Czech, S. F. Gugino, J. M. Davis, J. A. Russell, and R. H. Steinhorn Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, December 1, 2008; 295(6): L979 - L987. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Konduri, I. Bakhutashvili, A. Eis, and K. Pritchard Jr. Oxidant stress from uncoupled nitric oxide synthase impairs vasodilation in fetal lambs with persistent pulmonary hypertension Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1812 - H1820. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Said Mediators and modulators of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Pritchard Jr, Y. Shi, and G. G. Konduri Tetrahydrobiopterin in Pulmonary Hypertension: Pulmonary Hypertension in Guanosine Triphosphate-Cyclohydrolase-Deficient Mice Circulation, April 26, 2005; 111(16): 2022 - 2024. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |